Key Takeaways on RSV Vaccination

Significant gaps in vaccination coverage among nursing home residents leaves vulnerable populations at risk for severe complications, report finds.

Use of in-room air purifiers with HEPA-14 filters did not result in a significant reduction of acute respiratory infections.

New research reveals gaps in respiratory syncytial virus (RSV) knowledge among older adults and emphasizes the impact community pharmacies can have at improving education and vaccine uptake.

Respiratory syncytial virus (RSV) vaccination is approximately 77% to 81% effective against hospital and emergency department encounters among older adults, study finds.

Respiratory syncytial virus (RSV) caused significant hospitalizations and severe outcomes in adults, especially those aged 75 years and older.

The vaccine proved a cumulative efficacy of 62.9% against respiratory syncytial virus (RSV)-related lower respiratory tract disease in older adults over 3 seasons.